Tech Company Financing Transactions
Aspreva Pharmaceuticals Funding Round
On 3/9/2004, Aspreva Pharmaceuticals raised $57 million in Series A funding from Credit Suisse, Axiom Venture Partners and Edbi.
Transaction Overview
Company Name
Announced On
3/9/2004
Transaction Type
Venture Equity
Amount
$57,000,000
Round
Series A
Investors
Proceeds Purpose
The company will use these proceeds to initiate and fund clinical trials in several autoimmune diseases with CellCept(R) (mycophenolate mofetil), its first licensed therapeutic.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
106 Allen Rd.
Basking Ridge, NJ 07920
USA
Basking Ridge, NJ 07920
USA
Phone
Website
Email Address
Not Recorded
Overview
Aspreva's novel business model, based on asset partnering, is revolutionizing pharmaceutical partnering and bringing desperately needed evidence-based medicines to underserved patient populations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Stephen Holmes
Controller
Katie Passalacqua
Controller
Karen Wilson
Browse more venture capital transactions:
Prev: 3/8/2004: Voltaire venture capital transaction
Next: 3/9/2004: Agitar Technologies venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs